Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' Maintained
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cowen Downgrades Sarepta Therapeutic (SRPT) to Market Perform
February 27, 2015 9:15 AM ESTCowen downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform and removed its price target (prior $19.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $13.82 yesterday.
... MoreBaird Maintains Neutral View on Sarepta Therapeutic (SRPT) Post Q4
February 27, 2015 9:07 AM ESTBaird analyst Brian Skorney reiterated a Neutral rating and $16 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q4 results.
Skorney commented, "No change to outlook following 4Q14. We're remaining on the sidelines here after the 4Q14 update didn't give us enough... More
Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015
February 26, 2015 7:07 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.94), $0.12 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $27 thousand versus the consensus estimate of $1.56 million.
Cash and Other Investments of $211 Million at Year End 2014.NDA submission for eteplirsen planned for mid-year 2015 -Plan to discuss new data and NDA submission with FDA in 2nd QuarterLast month we released 168 week data from our Phase IIb study of eteplirsen. We believe the long-term safety of our drug with the continued ambulation and stability of pulmonary... More
